Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the effectiveness of acupressure point P6 stimulation versus intravenous ondansetron plus metoclopramide versus no antiemetic prophylaxis during elective cesarean section under regional anesthesia.
The design of the study consists of the randomization of subjects undergoing cesarean section with regional anesthesia in one of three groups. The study is not blinded; as the participants will know which method they are being treated with because of the difference in site and nature of the acupuncture point P6 stimulation. The randomization of patients will be done by a computer to avoid bias before the informed consent form (ICF) is signed by the patients. The computer will generate three sets of random numbers for the three groups. Once the consent form is signed, the investigator will allocate the patients serially to the groups having those numbers . The randomization will be created before the study begins and will assign 180 subjects into one of the three groups to receive the treatment as follows:
Group I (n=60): Will be the control group patients and will not be given traditional medical therapy nor will receive acupuncture point P6 stimulation prior to administration of the standardized epidural anesthesia, as outlined below.
Group II (n=60): Will receive traditional medical management, consisting of 10 mg metoclopramide IV and 8 mg of ondansetron IV immediately prior to administration of the standardized regional anesthesia, as outlined below.
Group III (n=60): Will receive acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia, as outlined below.
After the subjects have been randomly assigned to one of the three groups, subjects will receive the standardized regional anesthesia consisting of 2 milliliters (10 milligrams) of 0.5% bupivicaine and 20 micrograms of fentanyl and 100 micrograms of epinephrine. Patients will offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea every experienced).
An Apfel score, which is used to predict the risk of experiencing post-operative nausea and vomiting (PONV), will also be determined with each subject.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia | |
| Metoclopramide, Ondansetron | Active Comparator | 10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia |
|
| Acupressure Point P6 stimulator | Experimental | Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Acupressure Point P6 stimulator | Device | This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia. |
| Measure | Description | Time Frame |
|---|---|---|
| Nausea | The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. | During the surgical procedure |
| Vomiting | The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | During the surgical procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Nausea During Stage I (After the Administration of CSE and Until Eversion of the Uterus) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage I. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shaul Cohen, MD | Robert Wood Johnson University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Robert Wood Johnson University Hospital | New Brunswick | New Jersey | 08901 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23076903 | Background | Afolabi BB, Lesi FE. Regional versus general anaesthesia for caesarean section. Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD004350. doi: 10.1002/14651858.CD004350.pub3. | |
| 18043058 | Background | Arnberger M, Stadelmann K, Alischer P, Ponert R, Melber A, Greif R. Monitoring of neuromuscular blockade at the P6 acupuncture point reduces the incidence of postoperative nausea and vomiting. Anesthesiology. 2007 Dec;107(6):903-8. doi: 10.1097/01.anes.0000290617.98058.d9. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Control | No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia |
| FG001 | Metoclopramide, Ondansetron | 10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia Metoclopramide: 10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia. Ondansetron: 8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia. |
| FG002 | Acupressure Point P6 Stimulator | Acupuncture point P6 stimulation. The device was put on the patients in the operating room prior to administration of the regional anesthesia and was removed after the cesarean section was complete. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Control | No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia |
| BG001 | Metoclopramide, Ondansetron |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Nausea | The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. | Posted | Count of Participants | Participants | During the surgical procedure |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Control | No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Shaul Cohen, M.D., Professor of Clinical Anesthesiology, Director of Obstetric Anesthesia | Rutgers-Robert Wood Johnson Medical School | 732-937-8841 | cohensh@rwjms.rutgers.edu |
Not provided
| ID | Term |
|---|---|
| D009325 | Nausea |
| D014839 | Vomiting |
| D010549 | Personal Satisfaction |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D008787 | Metoclopramide |
| D017294 | Ondansetron |
| ID | Term |
|---|---|
| D001549 | Benzamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D062366 | para-Aminobenzoates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Metoclopramide | Drug | 10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia. |
|
|
| Ondansetron | Drug | 8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia. |
|
|
| During the surgical procedure |
| Nausea During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage II. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. | During the surgical procedure |
| Nausea During Stage III (After Replacement of the Uterus and to the Next 15 Minutes) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage III. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. | During the surgical procedure |
| Nausea During Stage IV (the Rest of the Time Until Arrival at PACU) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage IV. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. | During the surgical procedure |
| Vomiting During Stage I (After the Administration of CSE and Until Eversion of the Uterus) | The investigators will perform objective assessments of whether or not the patients have vomited during stage I. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | During the surgical procedure |
| Vomiting During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus) | The investigators will perform objective assessments of whether or not the patients have vomited during stage II. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | During the surgical procedure |
| Vomiting During Stage III (After Replacement of the Uterus and to the Next 15 Minutes) | The investigators will perform objective assessments of whether or not the patients have vomited during stage III. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | During the surgical procedure |
| Vomiting During Stage IV (the Rest of the Time Until Arrival at PACU) | The investigators will perform objective assessments of whether or not the patients have vomited during stage IV. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | During the surgical procedure |
| Satisfaction of Anti-emetic Treatment | Patients are asked their anti-emetic treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. | During the surgical procedure |
| Overall Anesthetic Care Satisfaction | Patients are asked their overall anesthetic care satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. | During the surgical procedure |
| 16158876 | Background | Chen HM, Chang FY, Hsu CT. Effect of acupressure on nausea, vomiting, anxiety and pain among post-cesarean section women in Taiwan. Kaohsiung J Med Sci. 2005 Aug;21(8):341-50. doi: 10.1016/S1607-551X(09)70132-9. |
| 15321185 | Background | Duggal KN, Douglas MJ, Peteru EA, Merrick PM. Acupressure for intrathecal narcotic-induced nausea and vomiting after caesarean section. Int J Obstet Anesth. 1998 Oct;7(4):231-6. doi: 10.1016/s0959-289x(98)80044-7. |
| 9085965 | Background | Fan CF, Tanhui E, Joshi S, Trivedi S, Hong Y, Shevde K. Acupressure treatment for prevention of postoperative nausea and vomiting. Anesth Analg. 1997 Apr;84(4):821-5. doi: 10.1097/00000539-199704000-00023. |
| 15385352 | Background | Gan TJ, Jiao KR, Zenn M, Georgiade G. A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. Anesth Analg. 2004 Oct;99(4):1070-1075. doi: 10.1213/01.ANE.0000130355.91214.9E. |
| 15947124 | Background | Golembiewski J, Chernin E, Chopra T. Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm. 2005 Jun 15;62(12):1247-60; quiz 1261-2. doi: 10.1093/ajhp/62.12.1247. |
| 16428565 | Background | Habib AS, Itchon-Ramos N, Phillips-Bute BG, Gan TJ; Duke Women's Anesthesia (DWA) Research Group. Transcutaneous acupoint electrical stimulation with the ReliefBand for the prevention of nausea and vomiting during and after cesarean delivery under spinal anesthesia. Anesth Analg. 2006 Feb;102(2):581-4. doi: 10.1213/01.ane.0000189217.19600.5c. |
| 10823097 | Background | Harmon D, Ryan M, Kelly A, Bowen M. Acupressure and prevention of nausea and vomiting during and after spinal anaesthesia for caesarean section. Br J Anaesth. 2000 Apr;84(4):463-7. doi: 10.1093/oxfordjournals.bja.a013471. |
| 8721471 | Background | Ho CM, Hseu SS, Tsai SK, Lee TY. Effect of P-6 acupressure on prevention of nausea and vomiting after epidural morphine for post-cesarean section pain relief. Acta Anaesthesiol Scand. 1996 Mar;40(3):372-5. doi: 10.1111/j.1399-6576.1996.tb04448.x. |
| 16492848 | Background | Ho CM, Tsai HJ, Chan KH, Tsai SK. P6 acupressure does not prevent emesis during spinal anesthesia for cesarean delivery. Anesth Analg. 2006 Mar;102(3):900-3. doi: 10.1213/01.ane.0000195553.82409.00. |
| 1859764 | Background | Lewis IH, Pryn SJ, Reynolds PI, Pandit UA, Wilton NC. Effect of P6 acupressure on postoperative vomiting in children undergoing outpatient strabismus correction. Br J Anaesth. 1991 Jul;67(1):73-8. doi: 10.1093/bja/67.1.73. |
| 9024025 | Background | Stein DJ, Birnbach DJ, Danzer BI, Kuroda MM, Grunebaum A, Thys DM. Acupressure versus intravenous metoclopramide to prevent nausea and vomiting during spinal anesthesia for cesarean section. Anesth Analg. 1997 Feb;84(2):342-5. doi: 10.1097/00000539-199702000-00018. |
| 12411789 | Background | White PF, Issioui T, Hu J, Jones SB, Coleman JE, Waddle JP, Markowitz SD, Coloma M, Macaluso AR, Ing CH. Comparative efficacy of acustimulation (ReliefBand) versus ondansetron (Zofran) in combination with droperidol for preventing nausea and vomiting. Anesthesiology. 2002 Nov;97(5):1075-81. doi: 10.1097/00000542-200211000-00008. |
| 11226090 | Background | Zarate E, Mingus M, White PF, Chiu JW, Scuderi P, Loskota W, Daneshgari V. The use of transcutaneous acupoint electrical stimulation for preventing nausea and vomiting after laparoscopic surgery. Anesth Analg. 2001 Mar;92(3):629-35. doi: 10.1097/00000539-200103000-00014. |
| 34002866 | Derived | Griffiths JD, Gyte GM, Popham PA, Williams K, Paranjothy S, Broughton HK, Brown HC, Thomas J. Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section. Cochrane Database Syst Rev. 2021 May 18;5(5):CD007579. doi: 10.1002/14651858.CD007579.pub3. |
10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
Metoclopramide: 10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
Ondansetron: 8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
| BG002 | Acupressure Point P6 Stimulator | Acupuncture point P6 stimulation. The device was put on the patients in the operating room prior to administration of the regional anesthesia and was removed after the cesarean section was complete. |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | Acupressure Point P6 Stimulator | Acupuncture point P6 stimulation. The device was put on the patients in the operating room prior to administration of the regional anesthesia and was removed after the cesarean section was complete. |
|
|
|
| Primary | Vomiting | The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Nausea During Stage I (After the Administration of CSE and Until Eversion of the Uterus) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage I. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Nausea During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage II. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Nausea During Stage III (After Replacement of the Uterus and to the Next 15 Minutes) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage III. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Nausea During Stage IV (the Rest of the Time Until Arrival at PACU) | Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage IV. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Vomiting During Stage I (After the Administration of CSE and Until Eversion of the Uterus) | The investigators will perform objective assessments of whether or not the patients have vomited during stage I. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Vomiting During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus) | The investigators will perform objective assessments of whether or not the patients have vomited during stage II. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Vomiting During Stage III (After Replacement of the Uterus and to the Next 15 Minutes) | The investigators will perform objective assessments of whether or not the patients have vomited during stage III. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Vomiting During Stage IV (the Rest of the Time Until Arrival at PACU) | The investigators will perform objective assessments of whether or not the patients have vomited during stage IV. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Satisfaction of Anti-emetic Treatment | Patients are asked their anti-emetic treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| Secondary | Overall Anesthetic Care Satisfaction | Patients are asked their overall anesthetic care satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. | Posted | Count of Participants | Participants | During the surgical procedure |
|
|
|
|
| 0 |
| 60 |
| 0 |
| 60 |
| 0 |
| 60 |
| EG001 | Metoclopramide, Ondansetron | 10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia Metoclopramide: 10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia. Ondansetron: 8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia. | 0 | 60 | 0 | 60 | 0 | 60 |
| EG002 | Acupressure Point P6 Stimulator | Acupuncture point P6 stimulation. The device was put on the patients in the operating room prior to administration of the regional anesthesia and was removed after the cesarean section was complete. | 0 | 60 | 0 | 60 | 0 | 60 |
Not provided
Not provided
Not provided
| D062365 |
| Aminobenzoates |
| D001565 | Benzoates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D002723 | Chlorobenzoates |
| D062425 | Hydroxybenzoate Ethers |
| D062385 | Hydroxybenzoates |
| D006880 | Hydroxy Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010647 | Phenyl Ethers |
| D010636 | Phenols |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D002227 | Carbazoles |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006575 | Heterocyclic Compounds, 3-Ring |
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
| 0.0002 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| Chi-squared | 0.8 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| 0.0004 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| Chi-squared | 0.09 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| 0.07 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| Chi-squared | 0.7 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| 0.7 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| Chi-squared | 0.2 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| 0.2 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| Chi-squared | 0.1 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced nausea in the above 2 groups. |
| 0.0004 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| Chi-squared | 1 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| 0.07 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| Chi-squared | 0.6 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| 0.5 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| Chi-squared | 0.7 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| 1 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| Chi-squared | 0.5 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the number of people who experienced vomiting in the above 2 groups. |
| 0.2 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the mean satisfaction level in the above 2 groups. |
| Fisher Exact | 0.3 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the mean satisfaction level in the above 2 groups. |
| 0.5 |
| Equivalence |
Our null hypothesis is that there is no statistically significant difference between the mean satisfaction level in the above 2 groups. |
| Fisher Exact | 0.7 | Equivalence | Our null hypothesis is that there is no statistically significant difference between the mean satisfaction level in the above 2 groups. |